Drug Discovery World

OCTOBER 13, 2023

A UK-based study will investigate whether a common anti-viral medication could double up as a treatment for long Covid. The project involves teams from the University Hospitals of Derby and Burton NHS Foundation Trust and the University of Exeter, in collaboration with Gilead Sciences. appeared first on Drug Discovery World (DDW).

Medical Schools 147

Medical Schools Hospitals Virus Treatment 147

Drug Discovery World

JUNE 23, 2023

The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. The increases in Elevidys dystrophin expression and the functional results that we see can make a difference in the lives of our patients.”

FDA Approval 243

FDA Approval Therapies FDA Protein Expression 243

The Pharma Data

APRIL 27, 2023

There are no RSV vaccines or specific treatments currently available for older adults. RSV causes over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in adults aged 60 years and older each year in Europe.

Virus 40

Virus Vaccine Trials Clinical Trials 40

Drug Discovery World

JANUARY 11, 2024

Messenger RNA therapies are also currently being investigated in other rare inherited metabolic diseases – propionic and methylmalonic acidaemias – in global clinical trials sponsored by Moderna, including at Great Ormond Street Hospital for Children. We believe it can now do the same for rare diseases.”

Disease 147

Disease Research RNA Therapies 147

The Pharma Data

APRIL 8, 2022

Using a Human Lung Chip that replicates the structures and functions of the lung air sac, or “alveolus,” the research team discovered that applying mechanical forces that mimic breathing motions suppresses influenza virus replication by activating protective innate immune responses. During his Ph.D.

Virus 52

Virus Immune Response Disease Clinical Trials 52

Broad Institute

FEBRUARY 8, 2024

By Allessandra DiCorato February 8, 2024 Credit: NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland Scanning electron image of the Lassa virus budding off a cell. Other scientists had discovered that this gene was critical for the Lassa virus to enter cells.

Research 82

Research Virus Hospitals FDA Approval 82

Drug Discovery World

JULY 7, 2023

They found that patients with more frequent antibiotic exposure in the past three years were at higher odds of experiencing severe Covid-19 outcomes, including hospital admission and 30-day mortality. Plus, using a range of antibiotics was more likely to be associated with Covid-19 hospital admission.

Hospitals 130

Hospitals Virus Research Treatment 130

Drug Discovery World

SEPTEMBER 13, 2023

At the end of 2022, the company launched GNC-501, a Phase II trial evaluating the clinical efficacy of a six-month treatment with temelimab on the improvement of cognitive impairment and/or fatigue in Long Covid patients who are positive for the presence of W-ENV protein in their blood. times more than the control group.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. 27, 2021 — Promising new data on two antibody cocktails suggest these therapies can keep COVID-19 patients out of the hospital and even prevent illness altogether in some people. All tested negative for the virus but live with someone who has COVID-19.

Treatment 52

Treatment Trials Hospitals Virus 52

The Pharma Data

DECEMBER 9, 2020

9, 2020 — In a sign that the COVID-19 pandemic is entering its most dire stage yet, new federal data show that more than a third of Americans now live in areas where hospitals are critically short of intensive care beds. WEDNESDAY, Dec. When you don’t have that capacity, that means people will die.”

Hospitals 52

Hospitals Doctors Virus Government 52

The Pharma Data

FEBRUARY 1, 2021

HOUSTON, TX, February 01, 2021 /24-7PressRelease/ — It has been just over a year since the COVID-19 virus arrived in the United States, already claiming the lives of over 400,000 Americans. Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients.

Treatment 52

Treatment Hospitals Virus Pharmaceutical Companies 52

Drug Discovery World

JULY 3, 2023

The programme on the topic of Gamma Delta Immunotherapy explored a range of ways to take advantage of Gamma-delta T cell properties, as well as ways to enhance them for effective treatment. This included broad antigen recognition, multivalent responses and the lack of MHC restrictions.

Engineering 130

Engineering Virus Therapies Treatment 130

The Pharma Data

MARCH 23, 2022

“When the COVID-19 pandemic started, our multidisciplinary research teams switched our investigations of other viruses and bacteria to focus on a potential treatment for what was then a challenging new virus for us,” says Children’s Center microbiologist Lori Jones-Brando, Ph.D., alone each year.

Virus 52

Virus Immune Response Research Treatment 52

The Pharma Data

SEPTEMBER 10, 2020

The disruption to hospitals in England during the pandemic has meant the number of patients facing long waits for routine operations has soared. But there are some encouraging signs, with treatments happening in hospitals on the increase. Image copyright. Getty Images. The numbers coming to Accident and Emergency topped 1.7m

Hospitals 52

Hospitals Treatment Virus 52

The Pharma Data

MARCH 22, 2022

NYSE: PFE) announced today an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval. Pfizer Inc.

Treatment 52

Treatment Virus Hospitals RNA 52

The Pharma Data

NOVEMBER 10, 2020

Antibody Treatment Approved for Emergency Use Against Early COVID-19. 10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. ” The agency warned that it should not be used in patients who are already hospitalized with the illness. Professional. government.

Treatment 52

Treatment Government Hospitals FDA 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

The Pharma Data

APRIL 16, 2021

for the treatment of COVID-19 – as planned with the FDA – follows the modification of contracts with the U.S. 1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. This request is not due to any new safety concern. All sites in the U.S.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

Drug Discovery World

OCTOBER 31, 2022

The researchers suggest that non-pharmaceutical interventions, including masks, prophylactic antibody treatment, and anti-viral treatment after acquisition of the virus are important tools to consider for additional protection against severe Covid-19 in immunocompromised adults. . Lower protection despite boosters .

Vaccine 130

Vaccine Virus Hospitals Treatment 130

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

Drug Discovery World

FEBRUARY 27, 2023

The investigational gene therapy OTL-201 works by collecting a patient’s own blood stem cells and inserting a working copy of the SGSH gene using a modified virus, known as a lentiviral vector. The patient’s modified blood stem cells, now including a working copy of the SGSHgene, are then given back to the patient.

Therapies 130

Therapies Trials Virus Disease 130

The Pharma Data

FEBRUARY 12, 2022

“With the emergence of variants such as Omicron, treatment options remain limited. Lilly is pleased to provide another treatment option to help address the ongoing needs of patients and health care providers who continue to battle this pandemic.”

Treatment 40

Treatment Hospitals FDA Clinical Trials 40

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

DECEMBER 20, 2020

20 , 2020 /PRNewswire/ — The broad spectrum antiviral therapeutic, ‘hzVSF-v13(humanized Virus Suppressing Factor)’ being developed by ImmuneMed , is on track to progress as a treatment for the COVID-19 pneumonia patients. CHUNCHEON, South Korea , Dec. Media Contact.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

Drug Discovery World

MAY 25, 2023

3D spheroid and organoid models are of human origin and are bridging this gap, so Duncan is currently working to create an insulin resistant organoid, which has a biosensor to give a real-time read-out function, and will ultimately support the discovery of new treatments.

Research 130

Research Virus Drugs Disease 130

The Pharma Data

SEPTEMBER 1, 2020

The Phase 3 trial did not meet the primary or secondary endpoints compared with placebo and established hospital care. Overall, it did not help those with less severe cases of the virus and in some cases the trial environment led to COVID-19 pneumonia infections and even death in a few instances.

Trials 52

Trials Treatment Clinical Trials Vaccine 52

The Pharma Data

JULY 23, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. Roche’s Chief Medical Officer and Head of Global Product Development.

Treatment 52

Treatment Virus Clinical Trials Government 52

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 52

Trials Treatment Small Molecule Hospitals 52

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

The first indication that those hopes might be realized came from the announcement just a month ago of a 50 percent reduction in hospitalizations from the Merck and Ridgeback drug molnupiravir (originally developed with an NIH grant to Emory University, Atlanta). The drug targets a highly conserved, but essential, viral enzyme.

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. In order to do so, the DSMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the trial.

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

APRIL 22, 2023

Additional data includes a retrospective real-world study which demonstrated that Veklury treatment is associated with a lower risk of death from COVID-19 for people living with cancer. Since the beginning of the pandemic, Veklury has played a critical role in the treatment of hospitalized patients with COVID-19.

Hospitals 40

Hospitals Virus Pharmacokinetics Treatment 40

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 There was a 1.08 placebo; p=0.024).

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JUNE 26, 2021

The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. FDA has made Actemra/RoActemra available under an emergency access mechanism called an EUA as a treatment for certain patients with COVID-19.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

MARCH 9, 2021

They can prevent the HIV replication process by blocking key enzyme activity at this stage, which results in the formation of immature virus particles. A planned interim analysis showed treatment emergent resistance associated mutations in the 200 mg arm after dosing was complete. Kimberly Smith, M.D., Kimberly Smith, M.D.,

Treatment 52

Treatment RNA Pharmacokinetics Virus 52